


PTO/SB/08A				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/829,000
				Filing Date	April 21, 2004
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
				Examiner Name	
Sheet	1	of	4	Attorney Docket No.	PHA 42624.1 (01380/5/US)



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
SW	1	3,261,859		Knoll A.-G.	07/19/1966
	2	3,267,104		Janssen Pharmaceutica N.V.	08/16/1966
	3	4,338,322		Sato	07/06/1982
	4	4,466,972		Neumann	08/21/1984
	5	4,521,537		Kosley, Jr. et al.	06/04/1985
	6	4,652,561		Mohacsi et al.	03/24/1987
	7	4,663,325		Ohtaka et al.	05/05/1987
	8	4,572,909		Campbell et al.	02/25/1986
	9	4,678,783		Hidaka et al.	07/07/1987
	10	4,845,225		Schwender et al.	07/04/1989
	11	4,935,417		Pascal et al.	06/19/1990
	12	5,314,903		Axelsson et al.	05/24/1994
	13	5,466,823		Talley et al.	11/14/1995
	14	5,521,207		Graneto	05/28/1996
SW	15	5,633,272		Talley et al.	05/27/1997

Examiner Signature	SW	Date Considered	7/22/07
--------------------	----	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,000
				Filing Date	April 21, 2004
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
				Examiner Name	
Sheet	2	of	4	Attorney Docket No.	PHA 42624.1 (01380/5/US)

52	16	5,767,129		Yuen	06/16/1998
	17	5,932,598		Talley et al.	08/03/1999
	18	5,981,539		Axelsson et al.	11/09/1999
	19	6,034,256		Carter et al.	03/07/2000
	20	6,077,850		Carter et al.	06/20/2000
	21	6,306,912		Mueller	10/23/2001
	22	6,387,897		Snutch	05/14/2002
52	23	6,423,689		Booth et al.	07/23/2002

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
52	24	EP	0072620 /	A1	Recordati S.A.	07/09/1982	
	25	EP	0089167 /	A2	Pfizer Limited	03/08/1983	
	26	EP	0092936	A1	Taisho Pharmaceutical Co. Ltd.	04/13/1983	
	27	EP	0125803 /	A2	Fisons Plc	04/16/1984	
	28	EP	0132375 /	A2	Pfizer Limited	07/18/1984	
	29	EP	0145434 /	A2	Otsuka Pharmaceutical Co., Ltd.	12/03/1984	
52	30	EP	0173933 (abs) /	A1	Sattinger, Gerhard, Dr.	08/23/1985	

Examiner Signature	<i>S. Wang</i>	Date Considered	7/22/07
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,000
				Filing Date	April 21, 2004
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
				Examiner Name	
Sheet	3	of	4	Attorney Docket No.	PHA 42624.1 (01380/5/US)

31	EP	0184257	A1	Janssen Pharmaceutica N.V.	11/22/1985	
32	EP	0218996	A2	Yason S.r.L.	10/01/1986	
33	EP	0257616	A2	The Green Cross Corporation	08/25/1987	
34	EP	0358418	A1	Sankyo Company Limited	09/01/1989	
35	EP	0366548	A1	Yuhan Corporation Ltd.	10/25/1989	
36	EP	0372934	A2	The Wellcome Foundation Limited	12/06/1989	
37	EP	0372940	A2	Allergan, Inc.	12/07/1989	
38	EP	0400495	A1	Farmitalia Carlo Erba S.r.L.	05/25/1990	
39	EP	0404359	A1	Pfizer Limited	05/25/1990	
40	EP	0414421	A2	Richter Gedeon Vegyeszeti Gyar R.T.	08/09/1990	
41	EP	0424901	A1	The Green Cross Corporation	10/24/1990	
42	EP	0441539	A2	Tanabe Seiyaku Co., Ltd.	01/31/1991	
43	EP	0467435	A2	Akzo N.V.	06/20/1991	
44	EP	0520200	A2	Neurosearch A/S	05/27/1992	
45	EP	0559569	A1	Bristol-Myers Squibb Company	03/04/1993	
46	WO	91/07980	A1	Neurex Corporation	06/13/1991	
47	WO	92/01672	A1	Novo Nordisk A/S	02/06/1992	
48	WO	92/04338	A1	The UpJohn Company	03/19/1992	
49	WO	92/14709	A2	Cambridge Neuroscience Inc.	09/03/1992	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>PTO/SB/08A</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/829,000
				Filing Date	April 21, 2004
				Confirmation Number	
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	
Examiner Name					
Sheet	4	of	4	Attorney Docket No.	PHA 42624.1 (01380/5/US)

50	WO	96/07415	A1	Universite De Montreal	03/14/1996	
51	WO	96/07641 (abs)	A1	Nippon Shinyaku Co., Ltd.	03/14/1996	
52	WO	97/45115	A1	Trophix Pharmaceuticals, Inc.	12/04/1997	
53	WO	98/03484	A1	Merck Frosst Canada Inc.	01/29/1998	
54	WO	99/54350	A1	The University of Queensland	10/28/1999	
55	WO	99/55688	A1	Warner-Lambert Company	11/04/1999	
56	WO	00/24719	A1	Abbott Laboratories	05/04/2000	
57	WO	00/48584	A2	Ortho-McNeil Pharmaceutical, Inc.	08/24/2000	

#### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
S	58	DE VRIES et al, "The Antiinflammatory Activity of Topically Applied Novel Calcium-Channel Antagonists", Inflammation, 1995, 19(2): 261-275	
	59	HICKS et al, "Neuroprotective Effects of the Neuronal Ca <sup>2+</sup> channel blockers, LY042826 and LY393615 in Vivo", European Journal of Pharmacology, 2000, 408: 241-248	
	60	KRATZER et al, "Simulation of Primary Haemostasis in Vitro", Haemostasis, 1985, 15: 357-362	
S	61	SONG et al, "(S)-4-Methyl-2-(methylamino)pentanoic Acid [4,4-Bis(4-fluorophenyl)butyl]amide Hydrochloride, a Novel Calcium Channel Antagonist, Is Efficacious in Several Animal Models of Pain", Journal of Medicinal Chemistry, 2000, 43(19): 3474-3477	

Examiner Signature	<i>S. W. [Signature]</i>	Date Considered	7/22/07
--------------------	--------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.